Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 17Recruiting 5Terminated 3Not yet recruiting 2Active not recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Lung Neoplasms 10Breast Neoplasms 10Uterine Cervical Neoplasms 9Lymphoma 8Squamous Cell Carcinoma of Head and Neck 7Prostatic Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Head and Neck Neoplasms 7Lymphoma, Large B-Cell, Diffuse 6Sarcoma 5Melanoma 5Lymphoma, Follicular 5Leukemia 5Colorectal Neoplasms 5Adenocarcinoma of Lung 5Small Cell Lung Carcinoma 4Rectal Neoplasms 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid, Acute 4Leukemia, Lymphocytic, Chronic, B-Cell 4Glioblastoma 4Central Nervous System Neoplasms 4Carcinoma, Hepatocellular 4Burkitt Lymphoma 4Ovarian Neoplasms 3Neoplasms 3

Interventions

tremelimumab 4Cystoscopy 3durvalumab 2avelumab 2Paclitaxel 2Gemcitabine 2Docetaxel 2Cisplatin 2vocimagene amiretrorepvec 1vinflunine 1trebananib 1trastuzumab duocarmazine 1pegfilgrastim 1merphos 1infigratinib 1erdafitinib 1efineptakin alfa 1copanlisib 1atezolizumab 1Vinblastine 1Trastuzumab 1Taxes 1TAS-116 1Specimen Handling 1Sirolimus 1Rosiglitazone 1Ropivacaine 1Rogaratinib 1Radiotherapy 1Polymerase Chain Reaction 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Urinary Bladder Neoplasms × Radiotherapy × Clear all
NCT03150836 2017-10-19

Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer

University of California, San Francisco

Phase 2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡